WO2025201672 - MIXTURE OF HMOS AND BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM
National phase entry is expected:
Publication Number
WO/2025/201672
Publication Date
02.10.2025
International Application No.
PCT/EP2024/084924
International Filing Date
05.12.2024
Title **
[English]
MIXTURE OF HMOS AND BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM
[French]
MÉLANGE DE HMO ET DE MICRO-ORGANISME TRANSITIONNEL DE BIFIDOBACTERIUM LONGUM
Applicants **
SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Inventors
BOULANGE, Claire Laurence Lucie Marie
CAVIN, Jean-Baptiste
CIARLO, Eleonora
DUBOUX, Stéphane
KWONG CHUNG, Cheong Kwet Choy
NOTI, Mario
Priority Data
24167396.1
28.03.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3428 | |
| EPO | Filing, Examination, Granting | 19551 | |
| Japan | Filing, Examination, Granting | 2616 | |
| South Korea | Filing, Examination, Granting | 3006 | |
| USA | Filing, Examination, Granting | 7640 |
Total:
36,241
Contact Us
Abstract[English]
transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and/or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and/or reducing the risk of allergen sensitisation, preventing and/or reducing the risk of developing a respiratory condition in a subject, and/or preventing and/or reducing the risk of developing asthma in a subject.[French]
présentant une identité nucléotidique moyenne (ANI) d'au moins 98 % avec CNCM I-5942. L'invention concerne également l'utilisation de la composition pour prévenir, pour réduire le risque et/ou pour traiter une infection chez un sujet. L'invention concerne en outre la composition destinée à être utilisée pour favoriser un bénéfice immunitaire à long terme chez un sujet, pour prévenir et/ou réduire le risque de sensibilisation aux allergènes, pour prévenir et/ou réduire le risque de développer une affection respiratoire chez un sujet et/ou pour prévenir et/ou réduire le risque de développer l'asthme chez un sujet.